前列舒通胶囊联合盐酸坦索罗辛缓释胶囊和非那雄胺片治疗良性前列腺增生患者的临床研究  

Clinical trial of Qianlieshutong capsules combined with tamsulosin hydrochloride sustained-release capsules and finasteride tablets in the treatment of patients with benign prostatic hyperplasia

作　　者：张鑫 梁泰生[1] 王坚 吴刚[1] 罗向东[1] ZHANG Xin;LIANG Tai-sheng;WANG Jian;WU Gang;LUO Xiang-dong(Department of Urology,Ruikang Hospital Affiliated to Guangxi University of Traditional Chinese Medicine,Nanning 530011,Guangxi Zhuang Autonomous Region,China)

机构地区：[1]广西中医药大学附属瑞康医院泌尿外科,广西壮族自治区南宁530011

出　　处：《中国临床药理学杂志》2022年第19期2273-2277,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察前列舒通胶囊联合盐酸坦索罗辛缓释胶囊和非那雄胺片治疗良性前列腺增生(benign prostatic hyperplasia,BPH)患者的临床疗效,及其对血清睾酮水平的影响。方法将115例BPH患者随机分为试验组58例和对照组57例。试验过程中试验组脱落4例,对照组脱落3例。对照组使用前列舒通胶囊1.2 g,每天3次,联合盐酸坦索罗辛口服0.2 g,每天3次进行治疗;试验组在对照组治疗的基础上,加用非那雄胺每次5 mg,每天3次,口服。2组持续治疗28 d。对比2组患者的临床疗效,国际前列腺症状评分(International Prostate Symptom Score,IPSS),慢性前列腺炎症状指数评分(National Institutes of Health Chronic Prostatitis Symptom Index,NIH-CPSI)、最大尿流率(maximum flow rate,Qmax)、残余尿量(residual urine vol-ume,RUV)、前列腺体积变化(prostate volume,PV)、T及雌二醇(Estradiol,E_(2))水平。结果治疗后,试验组和对照组的总有效率分别为94.44%(51例/54例)和79.63%(43例/54例),差异有统计学意义(P<0.05)。治疗28 d后,试验组和对照组的IPSS评分分别为(7.67±2.09)和(13.11±4.19)分,NIH-CPSI评分分别为(8.44±2.42)和(10.67±2.07)分,NIH-CPSI评分改善指数分别为(58.76±10.81)%和(48.68±10.74)%,Qmax值分别为(16.66±2.92)和(14.61±3.34)mL,RUV水平分别为(22.26±6.84)和(27.92±6.97)mL,PV水平分别为(27.31±7.46)和(31.62±7.02)cm3,血清睾酮水平分别为(988.59±78.73)和(853.84±84.96)ng·mL^(-1),E_(2)水平分别为(521.04±28.37)和(124.50±21.32)pg·mL^(-1),差异均有统计学意义(均P<0.05)。结论前列舒通胶囊联合盐酸坦索罗辛缓解胶囊和非那雄胺片治疗BPH的效果较好,可缩小前列腺体的体积,降低BPH患者炎症,提高患者血清睾酮水平,抑制二氢睾酮的转化,减轻BPH患者的痛苦。Objective To observe the clinical efficacy of Qianlieshutong capsules combined with tamsulosin hydrochloride sustained-release capsules and finasteride tablets in the treatment of patients with benign prostatic hyperplasia(BPH)and its effect on serum testosterone levels.Methods A total of 115 patients with BPH were randomly divided into the control group and the treatment group,with 58 cases in the treatment group and 57 cases in the control group.During the experiment,4 cases in the treatment group and 3 cases in the control group dropped out.The control group was treated with Qianlieshutong capsule 1.2 g,tid,combined with tamsulosin hydrochloride 0.2 g,m,tid.The treatment group was treated with basic finasteride 5 mg,tid.The two groups continued treatment for 28 d.The clinical efficacy,International Prostate Symptom Score(IPSS),National Institutes of Health Chronic Prostatitis Symptom Index(NIH-CPSI),maximum urinary flow rate(Qmax),residual urine volume(RUV),prostate volume change(PV),testosterone and estradiol(E_(2))levels were compared between the two groups.Results After treatment,the ORRs of the treatment group and control group were 94.44%(51 cases/54 cases)and 79.63%(43 cases/54 cases),respectively,and the difference was statistically significant(P<0.05).At 28 days after treatment,the IPSS scores of the control group were(7.67±2.09)and(13.11±4.19)points;the NIH-CPSI scores were(8.44±2.42)and(10.67±2.07)points,the NIH-CPSI score improvement indices were(58.76±10.81)%and(48.68±10.74)%;the Qmax values were(16.66±2.92)and(14.61±3.34)mL;the RUV levels were(22.26±6.84)and(27.92±6.97)mL;the PV levels were(27.31±7.46)and(31.62±7.02)cm3;the testosterone index levels were(988.59±78.73)and(853.84±84.96)ng·mL^(-1);the E_(2) index levels were(521.04±28.37)and(124.50±21.32)pg·mL^(-1),respectively,and the differences were statistically significant(all P<0.05).Conclusion Qianlieshutong capsules combined with tamsulosin hydrochloride sustained-release capsules and finasteride tablets are effective in the

关 键 词：前列舒通胶囊 盐酸坦索罗辛缓胶囊 非那雄胺片 良性前列腺增生 血清睾酮水平 疗效 联合用药 

分 类 号：R97[医药卫生—药品]